[Treatment of essential headache in developmental age with L-5-HTP (cross over double-blind study versus placebo)].
Thirty patients (mean age: 10.38 years) affected by primary headache were selected for a double-blind cross-over clinical trial. The patients were randomized into 2 homogeneous groups of 15 and treated for 12 weeks with L-5-HTP (100 mg/day) and placebo as per the following design: placebo - L-5-HTP (group A) and L-5-HTP - placebo (group B). Evaluation was carried out every 3 weeks by the Migraine Index supplying a general assessment of the attacks, i.e. severity, duration and frequency. The decrease in mean score values was directly proportional to L-5-HTP treatment, and statistical significance (Wilcoxon's test) was observed only for L-5-HTP in both groups, from 0.05 to 0.01. Improvement, as evaluated by CGI on percentage distribution of the patients, was homogeneous in both groups.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000293:Adolescent; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010919:Placebos
D010919:Placebos; D006916:5-Hydroxytryptophan
Trattamento della cefalea essenziale in età evolutiva con L-5-HTP (Studio in doppio-cieco "cross over" verso placebo).